| Status: | Laboratory PI, Senior Clinical Fellow |
| Address: |
Clinic I of Internal Medicine |
| Phone: | +49 221/478 5969 |
| Fax: | +49 221/478 88847 |
| E-Mail: | marco.herling@uk-koeln.de |
| Nationality: | German |
Education
| 1992 - 1999 |
Medical School, Martin-Luther-University (MLU), Halle-Wittenberg, Germany |
| 1994 - 1999 |
Doctoral degree “Dr. med.”, Institute of Pathology, MLU |
| 2002 - 2004 |
NIH Physician Scientist Training Program (curriculum for PhD in clinical research, mentor E.J. Freireich, MD), MDACC; Project and Thesis: “Bayesian statistics and novel trial designs in a proposal for T-PLL” |
| 2005 |
Graduate Course (2 semester): The role of Physicians and Scientists in the Business World, Harvard Medical School, MIT Boston and MDACC |
Professional and Research Experience
| 04/2000 - 04/2002 |
Clinical Resident / Fellow Internal Medicine, Department of Hematology / Oncology, University of Freiburg, Germany |
| 04/2002 – 11/2006 |
Postdoctoral Fellow, Department of Hematopathology, MDACC, Laboratory of Dan Jones, MD PhD |
| 12/2006 - present |
Senior Fellow, Department of Medicine I, Cologne University, Germany |
| 12/2006 - present |
Laboratory PI of “Lymphocyte signaling and oncoproteome”, Deutsche Krebshilfe Max-Eder junior group, Cologne University incl. CECAD |
| 07/2010 - present |
Adjunct Assistant Professor, Dept. of Hematopathology, MDACC |
| 07/2013 -present |
Co-founder and Scientific Board of DFG FOR1961 “Consortium for TCR-mediated Regulation and Oncogenesis in Lymphomas of T-cells; CONTROL-T” |
Awards and Honours (selected)
| 1997-1998 |
Stipend by IALS - Biomedical Sciences Exchange Program (2-semester integrated Medical School curriculum at MDACC, Dept. of Lymphoma) |
| 05/2004 - 11/2007 |
Odyssey Special Fellow Award, MDACC |
| 06/2006 - 12/2010 |
Deutsche Forschungsgemeinschaft - Junior Investigator Award |
| 08/2008 - 2015 |
Deutsche Krebshilfe Max-Eder Junior Group Award |
Contributions to the Scientific Society
|
Ad hoc journal reviewer: |
|
Appointed grant revisions: |
|
Activity in editorial board: |
Professional Memberships
| 2002 |
American Society of Hematology (ASH) |
| 2003 |
German Society of Hematology and Oncology (DGHO) |
| 2004 |
American Society of Clinical Oncology (ASCO) |
| 2010 |
German Society of Internal Medicine (DGIM) |
| 2011 |
German Society of Medical Intensive Care and Acute Medicine (DGIIN) |
| 2013 |
Deutsche Gesellschaft für Ultraschall in der Medizin e.V. (DEGUM) |
List of the five most important publications
Prinz C, Vasyutina E, Lohmann G, Schrader A, Romanski S, Hirschhäuser C, Mayer P, Frias C, Herling CD, Hallek M, Schmalz HG, Prokop A, Mougiakakos D, Herling M. Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. Mol Cancer. 2015 Jun 4;14(1):114.
Vasyutina E, Boucas JM, Bloehdorn J, Aszyk C, Crispatzu G, Stiefelhagen M, Breuer A, Mayer P, Lengerke C, Döhner H, Beutner D, Rosenwald A, Stilgenbauer S, Hallek M, Benner A, Herling M. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia. 2015 Oct;29(10):2003-14.
Fedorchenko O, Stiefelhagen M, Peer Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G*, Herling M*. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood 2013 May 16;121(20):4126-36 (* shared, order as published).
Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M*, Burger JA*. Stromal cells modulate TCL1 expression, interacting AP-1 components, and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 2012 Aug;26(8):1812-20, (* shared, order as published).
Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and therapy resistance in chronic lymphocytic leukemia. Blood 2009 Nov 19;114(21):4675-86.
Patents and licensures: